The drug solidifies its place as a first-line treatment option in AML.
Gabriela Aponte-Melendez, PharmD
Advertisement
Articles by Gabriela Aponte-Melendez, PharmD
The program develops patient-centered oncology pharmacists through comprehensive training.
Advancements include novel combination therapies and improved diagnostic techniques.
Multiple P13K inhibitors have showed promise in treating genetically-mutated forms of breast cancer.
Advertisement
Latest Updated Articles
The Evolution of PI3K Inhibitors in the Treatment of Breast CancerOctober 22nd 2024
Advertisement
Advertisement
Trending on Pharmacy Times
1
Cyclosporiasis Cases Reach 5100: Investigators Zero In On Lettuce, Possible Taco Bell Link
2
Subcutaneous Olanzapine in Schizophrenia: Expanding the Utility of a Proven Therapy
3
Patient-Reported Outcomes, Machine Learning May Predict Breast Cancer Recurrence Earlier
4
Rural Health Transformation Efforts Offer an Opportunity for Pharmacy to Shine
5